Skip to main content
. 2012 Apr 28;62(2):259–271. doi: 10.1136/gutjnl-2011-301585

Figure 4.

Figure 4

Evaluation of oral metronomic topotecan (topo). Twelve mice were orthotopically injected with HT29 human colon cancer cell and treated with control vehicle, topotecan or topotecan plus pazopanib (pazo) (n=4). Mice were sacrificed after 10 weeks. Primary tumour weights (A) and metastatic spread (B) were significantly reduced by topotecan mono- or combination therapy. Green arrows indicate hepatic metastases